NEW YORK, Nov. 06, 2025 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today announced ...
Geneva, Switzerland, August 27, 2024 - Addex Therapeutics (SIX/NASDAQ: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators ...
NEW YORK & GENEVA--(BUSINESS WIRE)--Neurosterix, a biopharmaceutical company dedicated to the development of allosteric modulator therapeutics for underserved neurological disorders, launched today ...
Addex Therapeutics Ltd. has released promising results from its novel γ-aminobutyric acid subtype B receptor (GABA-B) positive allosteric modulator (PAM) chronic cough program. In models of chronic ...
Geneva, Switzerland, June 6, 2025-Addex Therapeutics (SIX: ADXN and Nasdaq: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric ...
Please provide your email address to receive an email when new articles are posted on . A Swiss biopharmaceutical company announced its launch with $63 million in Series A financing for research and ...
Neurosterix was spun-out of Addex in April 2024, raising $65 million in a Series A financing led by funds affiliated with Perceptive Advisors. Addex retains a 20% equity interest in Neurosterix.
Proceedings of the National Academy of Sciences of the United States of America, Vol. 119, No. 16 (April 19, 2022), pp. 1-10 (10 pages) Allosteric modulators of G-protein-coupled receptors (GPCRs) ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback